Empfehlen
RSS
google +
Druckfassung

Nachrichten (Alterung)

This section on health in the EU has been created as a trustworthy gateway to a wide range of information and data on health-related issues and activities at both European, national and international level. The content is produced by the European Commission, the Member States of the EU and the European Economic Area (EEA), plus EU candidate countries; by international organisations; and by pan-European non-governmental organisations in the area of public health.

EFSA opinion on the likelihood of BSE infectivity in specified risk material from cattle at different age groups    europa.eu

EFSA opinion on the likelihood of BSE infectivity in specified risk material from cattle at different age groups[...]

Success Stories - Unravelling the mystery of ageing    europa.eu

Ageing is a complex process. It happens in every part of the body, not just specific cell or tissue types. Even psychological factors and stress can play a role. The EU-funded project NINA took a mul[...]

Promising drug for Parkinson's disease: Study supports fast track to clinical trials    epda.eu.com

A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson's disease, scientists from the University of Sheffield ha[...]

Roche will use app to track Parkinson's symptoms in drug trial    epda.eu.com

Roche Pharma Research and Early Development, a division of Roche Pharmaceuticals, has developed a new mobile app to measure Parkinson's disease symptoms.[...]

EFSA publishes advice on the consumption of young sheep and goats - coming from TSE affected flocks    europa.eu

EFSA publishes advice on the consumption of young sheep and goats - coming from TSE affected flocks[...]

EFSA assesses safety of GM maize hybrids: no adverse effects expected on human and animal health and on the environment    europa.eu

EFSA assesses safety of GM maize hybrids: no adverse effects expected on human and animal health and on the environment[...]

Cell therapy for Parkinsons: Functional role of host immune response on survival & differentiation of dopaminergic neuroblasts    epda.eu.com

The analysis of the available data leads authors to conclude that the modulation of the innate immune response after transplantation can increase the success of future clinical trials in PD by enhanc[...]

Amarantus opens clinical trial site & patient enrolment for eltoprazine phase 2b study in Parkinsons levodopa-induced dyskinesia    epda.eu.com

Amarantus BioScience Holdings, Inc., a biotechnology company announced that the first clinical trial site is now open for enrolment for the Phase 2b study of its lead product candidate eltoprazine fo[...]

The National Parkinson Foundation Launches New and Improved Parkinson.org    epda.eu.com

The National Parkinson Foundation announces today the official launch of a redesigned website, www.parkinson.org, devoted to increasing awareness and understanding of Parkinson's disease by offering [...]

Dutch king & queen visit children in hospital and learn about Parkinson's research    epda.eu.com

Dutch King Willem-Alexander and Queen Maxima visited children at Helen DeVos Children's Hospital and toured research labs at Van Andel Institute on Tuesday, June 2.[...]

The National Parkinson Foundation removes barriers to expert Parkinson's care through telemedicine    epda.eu.com

The National Parkinson Foundation (NPF) announced today that the Connect.Parkinson national research study, comparing telemedicine care delivered to remote patients from a Parkinson's disease centre [...]

Global Kinetics raises $14.8m to take its Parkinson's tech to the US    epda.eu.com

Australian health technology company Global Kinetics Corporation (GKC) has raised $14.8 million to expand its Parkinson's disease treatment technology to the United States.[...]

Parkinson's Disease Foundation Announces Newest Series of Community-Driven Online Seminars    epda.eu.com

The Parkinson's Disease Foundation (PDF) is pleased to announce its sixth series of PD ExpertBriefings, free interactive seminars presented by leaders in Parkinson's disease research and care.[...]

A new tool for understanding Parkinson's disease    epda.eu.com

École Polytechnique Fédérale de Lausanne (EPFL) scientists have developed a new method that can accurately simulate the chemical modification of the protein behind Parkinson's disease. The techniqu[...]

Parkinson's Disease Foundation Announces Newest Series of Community-Driven Online Seminars    epda.eu.com

The Parkinson's Disease Foundation (PDF) is pleased to announce its sixth series of PD ExpertBriefings, free interactive seminars presented by leaders in Parkinson's disease research and care.[...]

Muhammad Ali Parkinson Center celebrates extraordinary accomplishments with unique patient testimonial    epda.eu.com

Having managed nearly 200,000 patient visits and conducted in excess of 12,000 education and wellness classes, the Muhammad Ali Parkinson Center in Phoenix is celebrating its extraordinary accomplish[...]

Biogen enters collaboration with the Parkinson's Institute and Clinical Center    epda.eu.com

Biogen and the Parkinson's Institute and Clinical Center today announced the formation of a strategic alliance focused on enhancing the understanding of the underlying biology of Parkinson's disease [...]

White Book on Parkinson's disease    epda.eu.com

At the 2nd National Meeting of Parkinson's Italia, people with Parkinson's from all over Italy met up in Vasto, Abruzzo, the national group together with the local associations have instigated a new [...]

Dopamine receptor mapping with PET imaging in Parkinson's disease    epda.eu.com

In this article authors aim to review the role of PET imaging in understanding the postsynaptic dopaminergic mechanisms in PD. PET studies have allowed us to gain important insights into the function[...]

Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease    epda.eu.com

Biotie announces the start of the Phase 3 clinical study of tozadenant, an investigational adenosine A2a receptor antagonist, in patients with Parkinson's disease (PD) experiencing levodopa related e[...]

Parkinson Bizkaia Association (ASPARBI) Campaign - 'I join the movement against Parkinson'    epda.eu.com

Parkinson Bizkaia Association (ASPARBI) recently launched the campaign 'I join the movement against Parkinson' with the aim of promoting an easily recognisable gesture which identifies Parkinson's di[...]

EEPO Review on Upskilling Unemployed Adults: The Organisation, Profiling and Targeting of Training Provision    europa.eu

EEPO's Review on Upskilling Unemployed Adults: The Organisation, Profiling and Targeting of Training Provision was published in June 2015.[...]

Reform of military pensions in Romania and other social developments in Cyprus and Hungary    europa.eu

Three new Flash Reports produced by the European Social Policy Network (ESPN) are now available and provide information on recent developments in social protection in Cyprus, Romania and Hungary.[...]

NHS England approves routine commissioning for Parkinson's treatment Duodopa    epda.eu.com

AbbVie welcomes the decision by NHS England to routinely commission Duodopa (Levodopa-carbidopa intestinal gel - LCIG) for the first time.[...]

UNC team uses cellular bubbles to deliver Parkinson's meds directly to brain    epda.eu.com

Researchers at the University of North Carolina at Chapel Hill have used exosomes tiny bubbles of protein and fat produced naturally by cells to bypass the body's defences and deliver a potent biopha[...]

Campaign success: NHS England to fund Duodopa    epda.eu.com

The NHS in England has announced they will fund Duodopa, a life-changing drug for people with advanced Parkinson's. This means that should a specialist Parkinson's clinician prescribe Duodopa, a pers[...]

Herantis Pharma granted almost 3 million Euro government loan for Parkinson study    epda.eu.com

Tekes, the Finnish Funding Agency for Innovation, has granted a 2,903,000 EUR R&D loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson's disease. The l[...]

Parkinson's disease with and without preceding essential tremor-similar phenotypes: a pilot study    epda.eu.com

The fact that non-motor symptoms were similar in ET-PD gives rise to the hypothesis that also the prodromal phase of PD is similar in ET patients later developing classical PD compared to individuals[...]

Diabetes drug found useless for Parkinson's    epda.eu.com

The diabetes drug pioglitazone (Actos) isn't likely to slow the progression of early Parkinson's disease, researchers reported.[...]

New study calls for partnering of Parkinson's research community with patient groups to improve effectiveness of clinical trials    epda.eu.com

Despite an urgent need for new medications, clinical trials in Parkinson's disease (PD) have a relatively low rate of success. The reasons for this are complex, prompting a group of investigators fro[...]

Adherence to medical plans for older people - Just Published - EU Bookshop    europa.eu

A European Innovation Partnership on Active and Healthy Ageing priority[...]

Impact of earlier use of NEUPRO (rotigotine transdermal patch) in Parkinson's disease patients discussed at first EAN congress    epda.eu.com

Results of the post-hoc analysis investigating the impact of 6-month earlier versus postponed initiation of NEUPRO (rotigotine transdermal patch) in patients with early-stage Parkinson's disease (PD)[...]

Parkinson disease appears associated with many cancers in Taiwan    epda.eu.com

Parkinson disease (PD) appeared associated with 16 types of cancer in a study in Taiwan, an effort to explain the association in an East Asian population because most prior research has been conducte[...]

NeuroDerm poster selected for blue ribbon highlights session during International Congress of Parkinson's & Movement disorders    epda.eu.com

NeuroDerm Ltd., a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that its poster presentation, [...]

Parkinson disease appears associated with many cancers in Taiwan    epda.eu.com

Parkinson disease (PD) appeared associated with 16 types of cancer in a study in Taiwan, an effort to explain the association in an East Asian population because most prior research has been conducte[...]

1 Hour More: A storytelling project to improve Parkinson's disease patients' quality of life    epda.eu.com

With the aim of raising public attention about Parkinson's disease (PD) at an international level, providing people with PD emotional and practical support, the European Parkinson's Disease Associati[...]

Rudeness and hostility blight lives of 69,000 with Parkinson's    epda.eu.com

An estimated 69,000 people in the UK with Parkinson's have experienced hostility and rudeness from members of the public according to data released today by Parkinson's UK on the launch of Parkinson'[...]

Acorda presents data on inhaled levodopa therapy CVT-301 at International Congress of Parkinson's Disease and Movement Disorders    epda.eu.com

Acorda Therapeutics, Inc. today presented data from a Phase 2b clinical trial of CVT-301, an inhaled levodopa (L-dopa) under development for the episodic treatment of OFF episodes associated with Par[...]

Gene therapy prevents Parkinson's disease in animal model, says Pitt study    epda.eu.com

Gene therapy to reduce production of a brain protein successfully prevented development of Parkinson's disease in an animal study, according to researchers at the University of Pittsburgh School of M[...]

Acadia Pharmaceuticals presents integrated data from phase III program with Nuplazid™ (pimavanserin) for Parkinson's psychosis    epda.eu.com

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announce[...]

FDA approves brain implant to help reduce Parkinson's disease and essential tremor symptoms    epda.eu.com

The U.S. Food and Drug Administration today approved the Brio Neurostimulation System, an implantable deep brain stimulation device to help reduce the symptoms of Parkinson's disease and essential tr[...]

NTCELL clinical study in Parkinson's meets endpoints    epda.eu.com

Living Cell Technologies Limited (LCT) today announced results from a Phase I/IIa clinical study of NTCELL, an experimental regenerative cell therapy being studied as a disease-modifying agent in Par[...]

Melior Discovery receives patent approval from U.S. Patent and Trademark Office for new Parkinson's disease drug candidate    epda.eu.com

Melior Discovery, Inc. announced today that the United States Patent and Trademark Office (USTPO) has awarded a patent to the company for its Parkinson's disease candidate, MLR-1019. The patent cover[...]

Trust your gut: E. coli may hold one of the keys to treating Parkinson's    epda.eu.com

E. coli usually brings to mind food poisoning and beach closures, but researchers recently discovered a protein in E. coli that inhibits the accumulation of potentially toxic amyloids - a hallmark of[...]

Adamas receives Orphan drug designation for ADS-5102 for treatment of levodopa-induced dyskinesia associated with Parkinson's    epda.eu.com

Adamas Pharmaceuticals, Inc. today announced that the Food and Drug Administration (FDA) has granted orphan drug status to ADS-5102 for the treatment of levodopa-induced dyskinesia associated with Pa[...]

Congratulations to those who inspire others.Parkinson's Award Recipients    epda.eu.com

Join World Parkinson's Program in congratulating the recipients of the Dr.Rana International Parkinson's Community Service Award for 2014[...]

International Stem Cell Corporation presents data from Parkinson's disease program at AAN Annual Meeting    epda.eu.com

International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the company has be[...]

The Parkinson Alliance Reports Findings Pertaining to Exercise in Parkinson's Disease    epda.eu.com

The Parkinson Alliance (PA) completed their 18th survey based research, entitled Exercise in Parkinson's Disease With and Without DBS: A Closer Look from the Patient's Perspective, to investigate the[...]

My PD Journey: Urgent action needed to address challenges of Parkinson's disease in Europe with numbers set to double by 2030    epda.eu.com

My PD Journey, an unprecedented multi-stakeholder initiative led by the European Parkinson's Disease Association (EPDA), gathered last week with high-level EU officials and stakeholders from across E[...]

The 4th Copenhagen Parkinson Unity Walk    epda.eu.com

The 4th Copenhagen Parkinson Unity Walk on Saturday 30th May 2015, aims to increase public awareness of the illness as well as emphasising the importance of exercise for the wellbeing of people diagn[...]

Rudeness and hostility blight lives of 69,000 with Parkinson's    epda.eu.com

An estimated 69,000 people in the UK with Parkinson's have experienced hostility and rudeness from members of the public according to data released today by Parkinson's UK on the launch of Parkinson'[...]

Diary app helps track disease progress in Parkinson's patients    epda.eu.com

An iPad app diary may help track Parkinson's disease symptoms and have implications for clinical care, an ongoing study indicates.[...]

Boston Scientific announces strategic collaboration with Brainlab AG    epda.eu.com

Boston Scientific Corporation (NYSE: BSX) announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps improve patient treatment planning and surgical n[...]

Parkinson's Life a new 'webzine' for the international Parkinson's community now live!    epda.eu.com

A new and innovative magazine-style website has been launched to inspire and inform the international Parkinson's community.[...]

Critical Path Institute secures regulatory support for Parkinson's and Alzheimer's disease biomarkers    epda.eu.com

Critical Path Institute (C-Path) announced that the U.S. Food and Drug Administration (FDA) has issued three Letters of Support to C-Path's Coalition Against Major Diseases (CAMD) consortium for the [...]

The Michael J. Fox Foundation and Prothena partner to accelerate discovery of novel biomarkers for Parkinson's disease    epda.eu.com

The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Prothena Corporation plc, a late-stage clinical biotechnology company focused on the discovery, development and commercialisation of [...]

UNC team uses cellular bubbles to deliver Parkinson's meds directly to brain    epda.eu.com

Researchers at the University of North Carolina at Chapel Hill have used exosomes tiny bubbles of protein and fat produced naturally by cells to bypass the body's defences and deliver a potent biopha[...]

Amarantus receives notice of allowance for U.S. patent application for treatment of Parkinson's    epda.eu.com

Patent issuance will provide IP protection for lead product candidate eltoprazine for treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID)[...]

Zambon launches Xadago (safinamide) for patients with mid- to late-stage Parkinson's disease in Germany    epda.eu.com

Germany is the first country in which Xadago is available as an add-on to levodopa alone and in combination with other PD medications.[...]

Dutch king & queen visit children in hospital and learn about Parkinson's research    epda.eu.com

Dutch King Willem-Alexander and Queen Maxima visited children at Helen DeVos Children's Hospital and toured research labs at Van Andel Institute on Tuesday, June 2.[...]

The National Parkinson Foundation removes barriers to expert Parkinson's care through telemedicine    epda.eu.com

The National Parkinson Foundation (NPF) announced today that the Connect.Parkinson national research study, comparing telemedicine care delivered to remote patients from a Parkinson's disease centre [...]

Global Kinetics raises $14.8m to take its Parkinson's tech to the US    epda.eu.com

Australian health technology company Global Kinetics Corporation (GKC) has raised $14.8 million to expand its Parkinson's disease treatment technology to the United States.[...]

Amarantus opens clinical trial site & patient enrolment for eltoprazine phase 2b study in Parkinsons levodopa-induced dyskinesia    epda.eu.com

Amarantus BioScience Holdings, Inc., a biotechnology company announced that the first clinical trial site is now open for enrolment for the Phase 2b study of its lead product candidate eltoprazine fo[...]

Remarks by Vice-President Valdis Dombrovskis at the press conference on the social policy orientation debate    europa.eu

European Commission - Statement Strasbourg, 09 June 2015 Today, the Commission held an orientation debate on EU social policy and the main priorities of social policy for this mandate of the Commissi[...]

Research Headlines - Mapping cells for better Parkinson's research    europa.eu

Parkinson's disease is a common disorder with no cure available yet. An EU-funded project has produced a genetic and chemical map of the neurons affected by the disease, to support new research into [...]

Amarantus opens clinical trial site & patient enrolment for eltoprazine phase 2b study in Parkinsons levodopa-induced dyskinesia    epda.eu.com

Amarantus BioScience Holdings, Inc., a biotechnology company announced that the first clinical trial site is now open for enrolment for the Phase 2b study of its lead product candidate eltoprazine fo[...]

Dutch king & queen visit children in hospital and learn about Parkinson's research    epda.eu.com

Dutch King Willem-Alexander and Queen Maxima visited children at Helen DeVos Children's Hospital and toured research labs at Van Andel Institute on Tuesday, June 2.[...]

Global Kinetics raises $14.8m to take its Parkinson's tech to the US    epda.eu.com

Australian health technology company Global Kinetics Corporation (GKC) has raised $14.8 million to expand its Parkinson's disease treatment technology to the United States.[...]

The National Parkinson Foundation removes barriers to expert Parkinson's care through telemedicine    epda.eu.com

The National Parkinson Foundation (NPF) announced today that the Connect.Parkinson national research study, comparing telemedicine care delivered to remote patients from a Parkinson's disease centre [...]

Research seminar on self-employment    europa.eu

Supporting entrepreneurship and self-employment is an important part of the Europe 2020 Strategy for smart, sustainable and inclusive growth.[...]

Events - Rheumatology & Aging Conference 2015 - 8-11 September 2015, Cambridge, UK    europa.eu

This conference will focus on the cells that control the immune system, their function in health, disease and aging, and the role of inflammation on musculoskeletal diseases of aging. At the end of t[...]

The 4th Copenhagen Parkinson Unity Walk    epda.eu.com

The 4th Copenhagen Parkinson Unity Walk on Saturday 30th May 2015, aims to increase public awareness of the illness as well as emphasising the importance of exercise for the wellbeing of people diagn[...]

Gender gap in pensions in the EU - Just Published - EU Bookshop    europa.eu

Research note to the Latvian Presidency[...]

Innovative Financing: Opportunities for Active & Healthy Ageing (Brussels, 3 June 2015)    europa.eu

Innovative Financing: Opportunities for Active & Healthy Ageing (Brussels, 3 June 2015) - Directorate General for Health and Food Safety[...]

Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease    epda.eu.com

Study data confirm that LCIG is beneficial in the long-term treatment of advanced PD patients despite a decline in cognitive functions in a subgroup of patients, probably due to disease progression. [...]

Deep brain stimulation in Parkinson's disease: meta-analysis of randomized controlled trials    epda.eu.com

Although the number of RCTs obtained is small, the total sample size is relatively large, confirming the efficacy of DBS in the control of motor signs and improvement of patients' functionality and q[...]

Disclaimer

The European Commission is solely responsible for information present on EU-level websites, information present in the Portal originated by the Commission. National-level information is provided by the Member States concerned and Member States are solely responsible for the accuracy of the information. Likewise, the European Commission is not responsible for information on non-governmental organisations and international organisations websites. The European Union is committed to user privacy. Read more concerning the Legal Notice.
Further questions can be answered through the Contact page. The Health-EU portal supports principles and measures to increase the credibility of information on the net. It complies with the HONcode standard for trustworthy health information: verify here.